OBJECTIVES To assess immunogenicity of a single dose of live attenuated hepatitis A vaccine in Indian children, ten years after immunization. METHODS Of 143 children vaccinated in 2004, 121 children were evaluated in 2014, clinically and for anti-HAV antibodies. RESULTS 13 children were early vaccine failures who received two doses of HAV vaccine subsequently. 106 (98%) of 108 remaining chi...

Among persons who live until the age of 85 years, herpes zoster will develop in approximately half, with an incidence that seems to be increasing. Although the disease may be mild in healthy young adults, persons over the age of 50 years and those who are immunocompromised are more likely to have complications that include herpes zoster ophthalmicus and postherpetic neuralgia. The live attenuat...

Virion glycoproteins such as glycoprotein D (gD) are believed to be the dominant antigens of herpes simplex virus 2 (HSV-2). We have observed that mice immunized with a live HSV-2 ICP0- mutant virus, HSV-2 0ΔNLS, are 10 to 100 times better protected against genital herpes than mice immunized with a HSV-2 gD subunit vaccine (PLoS ONE 6:e17748). In light of these results, we sought to determine w...

Thirty-two seronegative pups were vaccinated at 8 weeks of age with modified-live canine distemper virus (CDV), canine adenovirus type-2 (CAV-2), and canine parvovirus (CPV) vaccine and at 12 weeks with a modified-live CDV, CAV-2, CPV, and killed rabies virus vaccine. An additional 31 seronegative pups served as age-matched, nonvaccinated controls. All test dogs were strictly isolated for 3 yea...

Live-attenuated retroviruses have been shown to be effective retroviral vaccines, but currently little is known regarding the mechanisms of protection. In the present studies, we used Friend virus as a model to analyze characteristics of a live-attenuated vaccine in protection against virus-induced disease. Highly susceptible mice were immunized with nonpathogenic Friend murine leukemia helper ...

background: the aim of present study was to evaluate the protective efficacy of live recombinant l. tarentolae expressing kmp11-ntgp96-gfp fusion as candidates for live engineered recombinant vaccine against visceral leishmaniasis in balb/c mice. methods: kmp-11 and nt-gp96 genes cloned into the pjet1.2/blunt cloning vector and then into pegfp-n1 expression vector. the kmp-11, nt-gp96 and gfp f...

The uniqueness of the dengue viruses (DENVs) and the spectrum of disease resulting from infection have made dengue vaccine development difficult. Several vaccine candidates are currently being evaluated in clinical studies. The candidate currently at the most advanced clinical development stage, a live-attenuated tetravalent vaccine based on the chimeric yellow fever-dengue virus (CYD-TDV), has...

The use of liposome as an adjuvant and a vaccine carrier has been cited previously in the literature. It has also been shown to be effective in enhancing the immunogenicity of vaccine candidates. BALB/c mice immunized subcutaneously with outer membrane protein (OMP) of Brucella abortus S19 vaccine strain entrapped in a commercial cationic liposome (S19-OMP-liposome) for vaccine delivery, showed...

Despite many years of research, a dengue vaccine is not available, and the more advanced live attenuated vaccine candidate in clinical trials requires multiple immunizations with long interdose periods and provides low protective efficacy. Here, we report important contributions to the development of a second-generation dengue vaccine. First, we demonstrate that a nonpropagating vaccine vector ...

an inactivated agalactia vaccine was prepared with mycoplasma agalactiae in fermenter. the culture was inactivated and subsequently adjuvanted with aluminum hydroxide gel. four sheep and four goats were immunized with the experimental vaccine. two doses of 1ml of vaccine were administered three weeks interval. monthly, blood samples were taken from the vaccinated animals up to the fifth month a...